Interleukin-4 in Pityriasis Lichenoides Chronica

March 16, 2025 updated by: Mona Mostafa Korany Mahmoud, Cairo University

Assessment of Interleukin-4 Tissue and Serum Levels in Pityriasis Lichenoides Chronica Patients : a Case- Control Study

assessment of the level of interleukin 4 (IL-4) in the lesional skin and serum of PLC patients and compare its level with healthy controls.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

measuring the level of Interleukin 4 in lesional skin and it's serum level using ELIZA in patients with Pityriasis lichenoides chronica and comparing the levels with healthy controls levels

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Patients with pityriasis lichenoides Chronica (PLC): either with the classical presentation papular or hypo-pigmented macules and patches that proved histopathologically to be PLC.
  • Both genders
  • Age group ≥ 8 years

Exclusion Criteria:

  • Patients with other skin diseases
  • Patient received treatment for PLC within period less than three months
  • Pregnant patients
  • Lactating patients

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: PLC patients
one skin biopsy (lesional) and serum sample will be taken from every patient
Procedure: skin biopsy and serum sample
skin biopsy from lesional skin and serum sample will be taken from each patient . also a skin biopsy and serum sample will be taken from each healthy control
Experimental: healthy controls
a skin biopsy and serum sample will be taken from each control sample
Procedure: skin biopsy and serum sample
skin biopsy from lesional skin and serum sample will be taken from each patient . also a skin biopsy and serum sample will be taken from each healthy control

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment of tissue and serum levels of interleukin 4 (IL -4) in pityriasis lichenoides chronica (PLC) patients and normal controls.
Time Frame: 6 months
measurement of tisssue and serum levels of interleukin 4 (IL -4) in pityriasis lichenoides chronica (PLC) patients and comparing them with normal controls to control and verify the hypothesisof involvement of IL-4 in the pathogenesis of PLC
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2025

Primary Completion (Estimated)

July 1, 2025

Study Completion (Estimated)

July 1, 2025

Study Registration Dates

First Submitted

March 16, 2025

First Submitted That Met QC Criteria

March 16, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 16, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Dermatology 20

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pityriasis Lichenoides

Clinical Trials on skin biopsy and serum sample

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe